A Phase 1a study to investigate the immunogenic potential of PIN-2 administered intravenously to patients with advanced solid tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Apr 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PIN 2 (Primary)
Indications Solid tumours
Focus Biomarker; First in man; Pharmacodynamics; Pharmacokinetics; Proof of concept
Sponsors PIN Pharma Inc

04 Jun 2019 Results assessing immune activation and safety of PIN- 2 administered intravenously to patients with advanced solid tumors, were presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
06 May 2019 According to a PIN Pharma Inc media release, data from this trial will be presented at the 55th Annual meeting of ASCO in Chicago on June 1 2019.
02 Jan 2019 According to a PIN Pharma Inc media release, this study is conducted by PIN Pharma's wholly owned Australian subsidiary, PIN Pharma Pty Ltd.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com